BioNxt Advances Commercial Strategy with Global Patents and U.S. Fast Track

BioNxt Solutions Inc., a leader in bioscience innovation, is pushing forward its commercialization plans. The company's sublingual drug delivery platform now enjoys extensive global patent protection. This includes European Patent No. 4539857, covering up to 39 EPC member states, and Eurasian Patent No. 051510, safeguarding eight states including Russia and Kazakhstan. In the U.S., a Track One fast-track patent filing promises faster patent processing within 9 to 12 months.

Targeting multiple sclerosis and myasthenia gravis, BioNxt’s lead product, BNT23001, leverages thin-film technology for better bioavailability and patient compliance. The company plans to partner with pharmaceutical firms through licensing agreements to enhance its drug delivery systems.

BioNxt CEO, Hugh Rogers, indicates that robust patent coverage and swift U.S. patent pathways enable effective commercialization. The firm aims to secure strategic partnerships and capitalize on its advanced drug delivery platform.